Gilead Sciences Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Gilead Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View analyst ratings for Gilead Sciences or view top-rated stocks.

13 brokerages have issued 12 month target prices for Gilead Sciences' stock. Their GILD stock forecasts range from $56.00 to $90.00. On average, they predict Gilead Sciences' share price to reach $72.07 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for Gilead Sciences or view top-rated stocks among Wall Street analysts.

Gilead Sciences' stock was trading at $72.61 on January 1st, 2022. Since then, GILD stock has decreased by 14.1% and is now trading at $62.36.
View the best growth stocks for 2022 here.

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Gilead Sciences.

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, April, 28th. The biopharmaceutical company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.35. The biopharmaceutical company earned $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a trailing twelve-month return on equity of 44.98% and a net margin of 16.43%. The company's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.08 EPS.
View Gilead Sciences' earnings history.

Gilead Sciences announced a quarterly dividend on Monday, May 2nd. Investors of record on Wednesday, June 15th will be paid a dividend of $0.73 per share on Wednesday, June 29th. This represents a $2.92 dividend on an annualized basis and a yield of 4.68%. The ex-dividend date of this dividend is Tuesday, June 14th.
View Gilead Sciences' dividend history.

Gilead Sciences(NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 4.68%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Gilead Sciences is 81.56%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 46.65% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

Gilead Sciences issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $6.20-$6.70 for the period, compared to the consensus earnings per share estimate of $6.50. The company issued revenue guidance of $23.80 billion-$24.30 billion, compared to the consensus revenue estimate of $24.48 billion.

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS).
View all of GILD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include First Financial Bank Trust Division (0.01%) and Insight Wealth Strategies LLC (0.00%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences.

GILD stock was acquired by a variety of institutional investors in the last quarter, including Insight Wealth Strategies LLC, and First Financial Bank Trust Division.
View insider buying and selling activity for Gilead Sciences or or view top insider-buying stocks.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GILD stock can currently be purchased for approximately $62.36.

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $78.22 billion and generates $27.31 billion in revenue each year. The biopharmaceutical company earns $6.23 billion in net income (profit) each year or $3.579990 on an earnings per share basis.

Gilead Sciences employs 14,400 workers across the globe.

Gilead Sciences was founded in 1987.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for Gilead Sciences is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.